Skip to main content

Advertisement

SpringerLink
Log in

SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Platinum-based (especially cisplatin) chemotherapy is the main treatment after surgery for ovarian cancer. Although the initial treatment is effective, chemotherapy resistance develops rapidly. Therefore, chemotherapy resistance has always been a huge obstacle in the treatment of ovarian cancer. Staphylococcal nuclease domain-containing protein 1 (SND1) is an evolutionarily conserved multifunctional protein that plays a role in promoting tumorigenesis under various stress states. In this study, using MTT and SKOV3 ovarian cancer cells deficient in SND1 were observed to be more apoptotic and to express more apoptotic protein after treatment with cisplatin through the MTT, clone formation, and flow cytometry assays, while cells overexpressing SND1 exhibited a decreased number of apoptotic cells and expression of apoptotic proteins. Moreover, SND1 can regulate the expression of Growth arrest-specific 6 (GAS6) and then activate the AKT signaling pathway to achieve the regulation of sensitivity to cisplatin-induced apoptosis in ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Capozzi VA, Rosati A, Turco LC, Sozzi G, Ricco M, Chiofalo B, Vizzielli G. Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option. Gland Surg. 2020;9:1112–7.

    Article  Google Scholar 

  2. Li H, Zeng J, Shen K. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 2014;290:1067–78.

    Article  CAS  Google Scholar 

  3. Christie EL, Bowtell DDL. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017;28:viii13–5.

    Article  CAS  Google Scholar 

  4. Westin SN, Louie-Gao M, Gupta D, Thaker PH. Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018. Future Oncol. 2021;17:4263–74.

    Article  CAS  Google Scholar 

  5. Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J. Molecular mechanisms of platinumbased chemotherapy resistance in ovarian cancer (review). Oncol Rep. 2022;47:1–11.

    Google Scholar 

  6. Yang J, Aittomaki S, Pesu M, Carter K, Saarinen J, Kalkkinen N, Kieff E, Silvennoinen O. Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. EMBO J. 2002;21:4950–8.

    Article  CAS  Google Scholar 

  7. Yang J, Valineva T, Hong J, Bu T, Yao Z, Jensen ON, Frilander MJ, Silvennoinen O. Transcriptional co-activator protein p100 interacts with snRNP proteins and facilitates the assembly of the spliceosome. Nucleic Acids Res. 2007;35:4485–94.

    Article  CAS  Google Scholar 

  8. Gao X, Zhao X, Zhu Y, He J, Shao J, Su C, Zhang Y, Zhang W, Saarikettu J, Silvennoinen O, Yao Z, Yang J. Tudor staphylococcal nuclease (Tudor-SN) participates in small ribonucleoprotein (snRNP) assembly via interacting with symmetrically dimethylated Sm proteins. J Biol Chem. 2012;287:18130–41.

    Article  CAS  Google Scholar 

  9. Su C, Zhang C, Tecle A, Fu X, He J, Song J, Zhang W, Sun X, Ren Y, Silvennoinen O, Yao Z, Yang X, Wei M, Yang J. Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G1/S phase transition, acting as a co-activator of E2F–1 in cell cycle regulation. J Biol Chem. 2015;290:7208–20.

    Article  CAS  Google Scholar 

  10. Elbarbary RA, Miyoshi K, Myers JR, Du P, Ashton JM, Tian B, Maquat LE. Tudor-SN–mediated endonucleolytic decay of human cell microRNAs promotes G1/S phase transition. Science. 2017;356:859–62.

    Article  CAS  Google Scholar 

  11. Fu X, Zhang C, Meng H, Zhang K, Shi L, Cao C, Wang Y, Su C, Xin L, Ren Y, Zhang W, Sun X, Ge L, Silvennoinen O, Yao Z, Yang X, Yang J. Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress. Cell Death Differ. 2018;25:1625–37.

    Article  CAS  Google Scholar 

  12. Sundstrom JF, Vaculova A, Smertenko AP, Savenkov EI, Golovko A, Minina E, Tiwari BS, Rodriguez-Nieto S, Zamyatnin AA, Valineva T, Saarikettu J, Frilander MJ, Suarez MF, Zavialov A, Stahl U, Hussey PJ, Silvennoinen O, Sundberg E, Zhivotovsky B, Bozhkov PV. Tudor staphylococcal nuclease is an evolutionarily conserved component of the programmed cell death degradome. Nat Cell Biol. 2009;11:1347-U1198.

    Article  Google Scholar 

  13. Duan Z, Zhao X, Fu X, Su C, Xin L, Saarikettu J, Yang X, Yao Z, Silvennoinen O, Wei M, Yang J. Tudor-SN, a novel coactivator of peroxisome proliferator-activated receptor gamma protein, is essential for adipogenesis. J Biol Chem. 2014;289:8364–74.

    Article  CAS  Google Scholar 

  14. Yu L, Di Y, Xin L, Ren Y, Liu X, Sun X, Zhang W, Yao Z, Yang J. SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFbeta1 response and breast cancer metastasis. Oncogene. 2017;36:3903–14.

    Article  CAS  Google Scholar 

  15. Cui XT, Zhang XX, Liu MH, Zhao CY, Zhang N, Ren YY, Su C, Zhang W, Sun XM, He JY, Gao XJ, Yang J. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics. 2020;112:3958–67.

    Article  CAS  Google Scholar 

  16. Gao X, Ge L, Shao J, Su C, Zhao H, Saarikettu J, Yao X, Yao Z, Silvennoinen O, Yang J. Tudor-SN interacts with and co-localizes with G3BP in stress granules under stress conditions. FEBS Lett. 2010;584:3525–32.

    Article  CAS  Google Scholar 

  17. Su C, Gao X, Yang W, Zhao Y, Fu X, Cui X, Zhang C, Xin L, Ren Y, Li L, Shui W, Yang X, Wei M, Yang J. Phosphorylation of Tudor-SN, a novel substrate of JNK, is involved in the efficient recruitment of Tudor-SN into stress granules. Biochim Biophys Acta (BBA) – Mol Cell Res. 2017;1864:562–71.

    Article  CAS  Google Scholar 

  18. Cui XT, Zhao CY, Yao XY, Qian BX, Su C, Ren YY, Yao Z, Gao XJ, Yang J. SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. RNA Biol. 2018;15:1364–75.

    Article  Google Scholar 

  19. Wang Y, Wang XT, Cui XT, Zhuo Y, Li HS, Ha CB, Xin LB, Ren YY, Zhang W, Sun XM, Ge L, Liu X, He JY, Zhang T, Zhang K, Yao Z, Yang X, Yang J. Oncoprotein SND1 hijacks nascent MHC-I heavy chain to ER-associated degradation, leading to impaired CD8(+) T cell response in tumor. Sci Adv. 2020. https://doi.org/10.1126/sciadv.aba5412.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wang X, Zhang C, Wang S, Rashu R, Thomas R, Yang J, Yang X. SND1 promotes Th1/17 immunity against chlamydial lung infection through enhancing dendritic cell function. PLoS Pathog. 2021;17:e1009295.

    Article  Google Scholar 

  21. Wu G, Ma Z, Hu W, Wang D, Gong B, Fan C, Jiang S, Li T, Gao J, Yang Y. Molecular insights of Gas6/TAM in cancer development and therapy. Cell Death Dis. 2017;8:e2700.

    Article  Google Scholar 

  22. Mullen MM, Lomonosova E, Toboni MD, Oplt A, Cybulla E, Blachut B, Zhao P, Noia H, Wilke D, Rankin EB, Kuroki LM, Hagemann AR, Hagemann IS, McCourt CK, Thaker PH, Mutch DG, Powell MA, Mosammaparast N, Vindigni A, Fuh KC. GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. Mol Cancer Res. 2022;20:265–79.

    Article  CAS  Google Scholar 

  23. Mao S, Wu Y, Wang R, Guo Y, Bi D, Ma W, Zhang W, Zhang J, Yan Y, Yao X. Overexpression of GAS6 promotes cell proliferation and invasion in bladder cancer by activation of the PI3K/AKT pathway. Onco Targets Ther. 2020;13:4813–24.

    Article  CAS  Google Scholar 

  24. Xin LB, Zhao R, Lei J, Song JC, Yu L, Gao R, Ha CB, Ren YY, Liu X, Liu YX, Yao Z, Yang J. SND1 acts upstream of SLUG to regulate the epithelial-mesenchymal transition (EMT) in SKOV3 cells. FASEB J. 2019;33:3795–806.

    Article  CAS  Google Scholar 

  25. Saarikettu J, Ovod V, Vuoksio M, Gronholm J, Yang J, Silvennoinen O. Monoclonal antibodies against human tudor-SN. Hybridoma. 2010;29:231–6.

    Article  CAS  Google Scholar 

  26. Liu L, Xiong W. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: a systematic review and meta-analysis. Medicine. 2021;100:e26849.

    Article  CAS  Google Scholar 

  27. Tanaka M, Siemann DW. Therapeutic targeting of the Gas6/Axl signaling pathway in cancer. Int J Mol Sci. 2021;22:9953.

    Article  CAS  Google Scholar 

  28. Di Stasi R, De Rosa L, D’Andrea LD. Therapeutic aspects of the Axl/Gas6 molecular system. Drug Discov Today. 2020;25:2130–48.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Prof. Lei Shi for kindly providing the lentivirus plasmids and the cell lines. This work was supported by the Science & Technology Development Fund of Tianjin Education Commission for Higher Education (2016YD18 to L. Xin).

Author information

Author notes

  1. Chuanbo Ha and Lihong Hu have contributed equally to this work.

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, 300070, China

    Chuanbo Ha, Lihong Hu, Yuanyuan Ren, Jie Yang & Lingbiao Xin

  2. Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Key Laboratory of Cellular and Molecular Immunology in Tianjin, Excellent Talent Project, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, Tianjin, China

    Jie Yang & Lingbiao Xin

Authors
  1. Chuanbo Ha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lihong Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuanyuan Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lingbiao Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JY and LX contributed to the study conception and design. Material preparation, data collection, and analysis were performed by CH, LH, and YR. The first draft of the manuscript was written by LX and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Lingbiao Xin.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ha, C., Hu, L., Ren, Y. et al. SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells. Med Oncol 39, 169 (2022). https://doi.org/10.1007/s12032-022-01763-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-022-01763-3

Keywords

Search

Navigation